Anti-Sm is associated with the early poor outcome of lupus nephritis

Sung Soo Ahn, Byung Woo Yoo, Jason Jungsik Song, YongBeom Park, Soo Kon Lee, Sang Won Lee

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Aim: We investigated whether anti-Smith (Sm) is associated with the outcome of kidney biopsy-proven lupus nephritis. Methods: We retrospectively analyzed clinical, laboratory and histological results in 90 patients with kidney biopsy-proven lupus nephritis. We defined persistent administration of immunosuppressants for more than 3 months after the kidney biopsy as early poor outcome of lupus nephritis. We compared baseline variables and delta values of lupus nephritis-related variables between patients with and without anti-Sm. The independent predictive values for early poor outcome were analyzed using logistic regression analysis. Results: The median age was 32.0 years old, and 77 patients (85.5%) were women. Anti-Sm was found in 44 of 90 patients (48.8%). When we analyzed the differences in delta values of variables reflecting the kidney function or the early poor outcome between patients with and without anti-Sm, we found significant difference in the early poor outcome between the two groups (80.0% of patients having anti-Sm vs. 56.5% of those not having anti-Sm, P = 0.022). In multivariate logistic regression analysis, along with age and Systemic Lupus Erythematosus Disease Activity Index, the presence of anti-Sm increased the potential of the early poor outcome of lupus nephritis (odds ratio 2.870, 95% confidence interval, 1.033, 7.976, P = 0.043). Conclusion: Our data suggest that anti-Sm identified at kidney biopsy might have a predictive value for the early poor outcome of biopsy-proven lupus nephritis during the follow-up period.

Original languageEnglish
Pages (from-to)897-902
Number of pages6
JournalInternational Journal of Rheumatic Diseases
Volume19
Issue number9
DOIs
Publication statusPublished - 2016 Sep 1

Fingerprint

Lupus Nephritis
Kidney
Biopsy
Logistic Models
Regression Analysis
Immunosuppressive Agents
Systemic Lupus Erythematosus
Odds Ratio
Confidence Intervals

All Science Journal Classification (ASJC) codes

  • Rheumatology

Cite this

Ahn, Sung Soo ; Yoo, Byung Woo ; Song, Jason Jungsik ; Park, YongBeom ; Lee, Soo Kon ; Lee, Sang Won. / Anti-Sm is associated with the early poor outcome of lupus nephritis. In: International Journal of Rheumatic Diseases. 2016 ; Vol. 19, No. 9. pp. 897-902.
@article{90c23e46d75b43f191e78b0bb8d91f74,
title = "Anti-Sm is associated with the early poor outcome of lupus nephritis",
abstract = "Aim: We investigated whether anti-Smith (Sm) is associated with the outcome of kidney biopsy-proven lupus nephritis. Methods: We retrospectively analyzed clinical, laboratory and histological results in 90 patients with kidney biopsy-proven lupus nephritis. We defined persistent administration of immunosuppressants for more than 3 months after the kidney biopsy as early poor outcome of lupus nephritis. We compared baseline variables and delta values of lupus nephritis-related variables between patients with and without anti-Sm. The independent predictive values for early poor outcome were analyzed using logistic regression analysis. Results: The median age was 32.0 years old, and 77 patients (85.5{\%}) were women. Anti-Sm was found in 44 of 90 patients (48.8{\%}). When we analyzed the differences in delta values of variables reflecting the kidney function or the early poor outcome between patients with and without anti-Sm, we found significant difference in the early poor outcome between the two groups (80.0{\%} of patients having anti-Sm vs. 56.5{\%} of those not having anti-Sm, P = 0.022). In multivariate logistic regression analysis, along with age and Systemic Lupus Erythematosus Disease Activity Index, the presence of anti-Sm increased the potential of the early poor outcome of lupus nephritis (odds ratio 2.870, 95{\%} confidence interval, 1.033, 7.976, P = 0.043). Conclusion: Our data suggest that anti-Sm identified at kidney biopsy might have a predictive value for the early poor outcome of biopsy-proven lupus nephritis during the follow-up period.",
author = "Ahn, {Sung Soo} and Yoo, {Byung Woo} and Song, {Jason Jungsik} and YongBeom Park and Lee, {Soo Kon} and Lee, {Sang Won}",
year = "2016",
month = "9",
day = "1",
doi = "10.1111/1756-185X.12880",
language = "English",
volume = "19",
pages = "897--902",
journal = "International Journal of Rheumatic Diseases",
issn = "1756-1841",
publisher = "Wiley-Blackwell",
number = "9",

}

Anti-Sm is associated with the early poor outcome of lupus nephritis. / Ahn, Sung Soo; Yoo, Byung Woo; Song, Jason Jungsik; Park, YongBeom; Lee, Soo Kon; Lee, Sang Won.

In: International Journal of Rheumatic Diseases, Vol. 19, No. 9, 01.09.2016, p. 897-902.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Anti-Sm is associated with the early poor outcome of lupus nephritis

AU - Ahn, Sung Soo

AU - Yoo, Byung Woo

AU - Song, Jason Jungsik

AU - Park, YongBeom

AU - Lee, Soo Kon

AU - Lee, Sang Won

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Aim: We investigated whether anti-Smith (Sm) is associated with the outcome of kidney biopsy-proven lupus nephritis. Methods: We retrospectively analyzed clinical, laboratory and histological results in 90 patients with kidney biopsy-proven lupus nephritis. We defined persistent administration of immunosuppressants for more than 3 months after the kidney biopsy as early poor outcome of lupus nephritis. We compared baseline variables and delta values of lupus nephritis-related variables between patients with and without anti-Sm. The independent predictive values for early poor outcome were analyzed using logistic regression analysis. Results: The median age was 32.0 years old, and 77 patients (85.5%) were women. Anti-Sm was found in 44 of 90 patients (48.8%). When we analyzed the differences in delta values of variables reflecting the kidney function or the early poor outcome between patients with and without anti-Sm, we found significant difference in the early poor outcome between the two groups (80.0% of patients having anti-Sm vs. 56.5% of those not having anti-Sm, P = 0.022). In multivariate logistic regression analysis, along with age and Systemic Lupus Erythematosus Disease Activity Index, the presence of anti-Sm increased the potential of the early poor outcome of lupus nephritis (odds ratio 2.870, 95% confidence interval, 1.033, 7.976, P = 0.043). Conclusion: Our data suggest that anti-Sm identified at kidney biopsy might have a predictive value for the early poor outcome of biopsy-proven lupus nephritis during the follow-up period.

AB - Aim: We investigated whether anti-Smith (Sm) is associated with the outcome of kidney biopsy-proven lupus nephritis. Methods: We retrospectively analyzed clinical, laboratory and histological results in 90 patients with kidney biopsy-proven lupus nephritis. We defined persistent administration of immunosuppressants for more than 3 months after the kidney biopsy as early poor outcome of lupus nephritis. We compared baseline variables and delta values of lupus nephritis-related variables between patients with and without anti-Sm. The independent predictive values for early poor outcome were analyzed using logistic regression analysis. Results: The median age was 32.0 years old, and 77 patients (85.5%) were women. Anti-Sm was found in 44 of 90 patients (48.8%). When we analyzed the differences in delta values of variables reflecting the kidney function or the early poor outcome between patients with and without anti-Sm, we found significant difference in the early poor outcome between the two groups (80.0% of patients having anti-Sm vs. 56.5% of those not having anti-Sm, P = 0.022). In multivariate logistic regression analysis, along with age and Systemic Lupus Erythematosus Disease Activity Index, the presence of anti-Sm increased the potential of the early poor outcome of lupus nephritis (odds ratio 2.870, 95% confidence interval, 1.033, 7.976, P = 0.043). Conclusion: Our data suggest that anti-Sm identified at kidney biopsy might have a predictive value for the early poor outcome of biopsy-proven lupus nephritis during the follow-up period.

UR - http://www.scopus.com/inward/record.url?scp=84988958316&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84988958316&partnerID=8YFLogxK

U2 - 10.1111/1756-185X.12880

DO - 10.1111/1756-185X.12880

M3 - Article

VL - 19

SP - 897

EP - 902

JO - International Journal of Rheumatic Diseases

JF - International Journal of Rheumatic Diseases

SN - 1756-1841

IS - 9

ER -